ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Net Product Revenue: $72.2 million for the first full year of commercial sales. Total Revenue: $84.3 million, including collaboration and supply revenue. R&D Expenses: $13.2 million, primarily for product development and clinical trials. SG&A Expenses: $230.1 million, reflecting commercialization investments. Gross to Net Retention: Low to mid-50% range, targeting around 50% at steady state. Cash Balance: $245 million in cash, cash equivalents, and short-term investments at year-end 2025. Commercial Coverage: Approximately 93% overall, with ongoing efforts to reduce prior authorization requirements. Sales Force Expansion: Increasing from 106 to 150 representatives, funded through reallocation of resources. Warning! GuruFocus has detected 5 Warning Signs with SPRY. Is SPRY fairly valued? Test your thesis with our free DCF calculator. Release Date: March 09, 2026 For the complete transcript of the earnings call, please re
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines [Seeking Alpha]Seeking Alpha
- ARS Pharmaceuticals (SPRY) was given a new $26.00 price target by Leerink Partners.MarketBeat
- ARS Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 3/9/26 - In-Line
SPRY
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 10-K
- 3/9/26 - Form 8-K
- SPRY's page on the SEC website